Controlled substances covered by the rule include stimulant medicines for attention-deficit/hyperactivity disorder, anxiety medications and medications for opioid use disorder. The extension is designed to give time to patients who have come to rely on telehealth and allow providers to get compliant.
Prior to the COVID-19 pandemic, patients needed at least one in-person visit to receive controlled substances. In February, the DEA proposed rolling back the COVID-19 era flexibility but faced backlash from telehealth groups.
Telehealth groups have continued to push the agency to create a registration pathway for remote prescriptions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
